Celon Pharma SA - Asset Resilience Ratio
Celon Pharma SA (CLN) has an Asset Resilience Ratio of 0.11% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CLN net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Celon Pharma SA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see CLN total asset value.
Liquid Assets Composition Over Time
This chart breaks down Celon Pharma SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read CLN liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł747.00K | 0.11% |
| Total Liquid Assets | zł747.00K | 0.11% |
Asset Resilience Insights
- Limited Liquidity: Celon Pharma SA maintains only 0.11% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Celon Pharma SA Industry Peers by Asset Resilience Ratio
Compare Celon Pharma SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Dr. Reddy's Laboratories Limited
F:RDDA |
Drug Manufacturers - Specialty & Generic | 11.36% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Apeloa Pharmaceutical Co Ltd
SHE:000739 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.35% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 0.66% |
Annual Asset Resilience Ratio for Celon Pharma SA (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Celon Pharma SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.13% | zł599.00K ≈ $164.85K |
zł457.46 Million ≈ $125.90 Million |
-8.74pp |
| 2024-12-31 | 8.87% | zł48.24 Million ≈ $13.28 Million |
zł543.79 Million ≈ $149.66 Million |
-5.56pp |
| 2023-12-31 | 14.44% | zł82.18 Million ≈ $22.62 Million |
zł569.31 Million ≈ $156.68 Million |
+1.02pp |
| 2022-12-31 | 13.42% | zł81.72 Million ≈ $22.49 Million |
zł608.93 Million ≈ $167.59 Million |
+2.14pp |
| 2021-12-31 | 11.28% | zł79.75 Million ≈ $21.95 Million |
zł707.14 Million ≈ $194.61 Million |
+11.28pp |
| 2020-12-31 | 0.00% | zł13.00K ≈ $3.58K |
zł703.64 Million ≈ $193.65 Million |
+0.00pp |
| 2019-12-31 | 0.00% | zł318.00 ≈ $87.52 |
zł591.35 Million ≈ $162.75 Million |
-9.66pp |
| 2018-12-31 | 9.66% | zł54.48 Million ≈ $14.99 Million |
zł563.67 Million ≈ $155.13 Million |
+9.68pp |
| 2017-12-31 | -0.02% | zł-90.59K ≈ $-24.93K |
zł525.05 Million ≈ $144.50 Million |
-0.33pp |
| 2016-12-31 | 0.31% | zł1.44 Million ≈ $395.83K |
zł464.32 Million ≈ $127.79 Million |
-0.07pp |
| 2015-12-31 | 0.38% | zł632.65K ≈ $174.12K |
zł168.29 Million ≈ $46.32 Million |
-0.18pp |
| 2014-12-31 | 0.56% | zł590.14K ≈ $162.42K |
zł105.44 Million ≈ $29.02 Million |
+0.35pp |
| 2013-12-31 | 0.21% | zł175.65K ≈ $48.34K |
zł82.59 Million ≈ $22.73 Million |
0.00pp |
| 2012-12-31 | 0.22% | zł150.13K ≈ $41.32K |
zł69.80 Million ≈ $19.21 Million |
-- |
About Celon Pharma SA
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.